Home / Research / Kidney cancer Kidney cancer: who works on it Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Publications since Nov 2025
Find fellow researchers One card per institution. Pick a target or a country to narrow the list.
Publications on this disease 151
Publications on this disease 38
2 of 2+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Running research funding Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.
NIH NCI · K99
Defining how mitochondrial metabolites reprogram cellular metabolism to control tumor growth
Northwestern University · Chicago, United States · US$99,022 awarded in fiscal year 2026 · until Aug 2028
NIH NCI · R50
Research specialist award to support PDIGREE (A031704) and implementation of NCI supported clinical trials at Simmons Comprehensive Cancer Center
Ut Southwestern Medical Center · Dallas, United States · US$164,513 awarded in fiscal year 2026 · until Aug 2031
NIH NCI · R44
Clinical Validation of a Synthetic Biology-Based Microbial Medicine to Treat Immunotherapy Refractory Solid Tumors
Rise Therapeutics, Llc · Rockville, United States · US$740,140 awarded in fiscal year 2026 · until Aug 2029
NIH NCI · R01
Fasting mimicking diet and cancer stem cells in Wilms tumor
Children's Hospital of Los Angeles · Los Angeles, United States · US$739,756 awarded in fiscal year 2026 · until Aug 2031
NIH NCI · R01
Southern Community Cohort Study
Vanderbilt University Medical Center · Nashville, United States · US$1,249,181 awarded in fiscal year 2026 · until Aug 2031
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
Identification of TILs-specific novel lincRNA and their functional importance in mediating immune response in renal cell carcinoma (REGULINC)
Turun Yliopisto · Turku, Finland · EU contribution €226,277 · until Sept 2027
European Commission (Horizon Europe) · HORIZON-ERC
IDENTIfication and tracking of cancer-prone cells in KIdney Tubules (IDENTIKIT)
Universita Vita-Salute San Raffaele · Milano, Italy · EU contribution €1,500,000 · until Dec 2029
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-ERC
TARGETING INHERITED CANCER SYNDROMES (INCANTAR)
Fondazione Telethon Ets · Roma, Italy · EU contribution €2,496,625 · until Aug 2028
European Commission (Horizon Europe) · HORIZON-RIA
First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma (CARE1)
Institut Gustave Roussy · Villejuif, France · EU contribution €5,577,694 · until Apr 2028 · 14 countries
European Commission (Horizon Europe) · HORIZON-RIA
COMputational Models FOR patienT stratification in urologic cancers – Creating robust and trustworthy multimodal AI for health care (COMFORT)
Klinikum Der Technischen Universität München (Tum Klinikum) · Muenchen, Germany · EU contribution €5,906,596 · until Mar 2027 · 7 countries
10 of 245 running projects, newest first. Listed amounts together: US$130.4m + €19.2m.
Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.
Trials that share participant data Trials whose registry record says individual participant data (IPD) will be shared.
No trial in this view states that it shares participant data.
Search by method Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
Integrative analysis prioritizes proteins associated with renal cell carcinoma and its risk factors.
JNCI Cancer Spectr, Sept 2026
Causal association between clonal hematopoiesis indeterminate potential and cancer: a Mendelian randomization study.
Exp Biol Med (Maywood), Jul 2026
A cross-ancestry genetic atlas of shared susceptibility between infectious diseases and cancer.
Funct Integr Genomics, Jul 2026
Profiling the Onco-metabolic Nexus and Improving Cancer Risk Prediction Performance: A Large-scale Cohort and Genome-Wide Pleiotropic Analysis.
Cancer Res Commun, May 2026
Identification of novel protein markers and therapeutic targets for common urological cancers by integrating large-scale human plasma proteome with the genome.
Sci Rep, Apr 2026
Hypocholesterolemia is a consequence, not a cause, of kidney cancer: A bidirectional Mendelian randomization study with NHANES 2001-2018.
Cancer Epidemiol, Apr 2026
Genetic landscape and functional exploration of kidney cancer predisposition in cross-ancestral populations.
Nat Commun, Apr 2026
Genetic evidence against a causal relationship between myocardial infarction and urological malignancies.
Can J Urol, Apr 2026
Use of Single-Cell Data and scPagwas Analysis to Identify T Cell Subsets and Construct a Prognostic Model for Clear Cell Renal Cell Carcinoma.
Hum Mutat, Apr 2026
Systematic assessment of obesity-related risk factors in renal cancer etiology: A longitudinal risk and Mendelian randomization analysis.
PLoS Med, Feb 2026
Paste an abstract See which targets of this disease your abstract mentions, and go to the people working on them.
Your abstract Matched in your browser only. The text is not sent, saved or logged.